Products for Research Use Only

Afuresertib

CAT: 0804-HY-15727-02Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15727-02Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively[1][2].
CAS Number
1047644-62-1
Product Name Alternative
GSK2110183; LAE002
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Akt; PKC; ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Afuresertib.html
Concentration
10mM
Purity
99.53
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)S1)N[C@@H](CC3=CC=CC(F)=C3)CN
Molecular Formula
C18H17Cl2FN4OS
Molecular Weight
427.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6 (11) :2646-2659.|[2]Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9 (6) :e100880
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Akt1; Akt2; Akt3; PKCβ; PKCη; PKCθ; ROCK
Citation 01
Cancers (Basel) . 2022 May 19;14 (10) :2493.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2024 Feb 1;187 (3) :624-641.e23.|Cold Spring Harb Mol Case Stud. 2022 Jan 10;8 (1) :a006140.|Food Chem Toxicol. 2025 Oct:204:115628.|Genes Dis. 2021 Aug 17;9 (2) :562-575.|Int J Cancer. 2020 Apr 1;146 (7) :1963-1978.|J Biol Chem. 2024 Feb;300 (2) :105641.|J Cell Biochem. 2024 Aug;125 (8) :e30613.|J Physiol. 2017 Jul 1;595 (13) :4207-4225.|Methods Mol Biol. 2018:1711:351-398.|Molecules. 2019 Apr 1;24 (7) :1260.|Research Square Print. October 27th, 2022.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|Theranostics. 2019 Jan 30;9 (4) :1096-1114.|Biomed Pharmacother. 2025 Nov:192:118707. |bioRxiv. 2025 Jun 16.|Patent. US20230147129A1.

Chemical Information

Afuresertib

N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide is a member of amphetamines.

CAS Number1047644-62-1
PubChem CID46843057
IUPAC NameN-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methylpyrazol-5-yl)thiophene-2-carboxamide
Molecular FormulaC18H17Cl2FN4OS
Molecular Weight427.3
XLogP4
Topological Polar Surface Area101
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Heavy Atom Count27
Formal Charge0
Complexity520
SMILES
CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl
InChI
InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
InChIKey
AFJRDFWMXUECEW-LBPRGKRZSA-N
Chemical Structure
2D Structure
2D structure of Afuresertib
CAS: 1047644-62-1
CID: 46843057
Formula: C18H17Cl2FN4OS
MW: 427.3
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight427.3
XLogP34
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass426.0484159
Monoisotopic Mass426.0484159
Topological Polar Surface Area101 Ų
Heavy Atom Count27
Formal Charge0
Complexity520
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes